explore -WSS

explore

author：leisure time 2025-09-30 01:13:46 - browse：3691

Adam's take main illustration — Molly Ferguson/STAT

Happy Groundhog Day eve. Some takes and thoughts on Bluebird Bio’s quest for gene therapy profits, a reality check on Vertex’s highly touted pain drug, and more ADC investor FOMO.

Bluebird and the case for gene therapy profits

Genetic treatments that are potential cures for inherited diseases are a huge medical advance, but can these transformational (and expensive) products become a profitable business? I’m not sure anyone knows yet for sure, but pay attention to Bluebird Bio over the next year for some clues.

Bluebird is unique among the biotech and pharma companies selling gene therapies (or CRISPR-based medicines) today because it has no other marketed products. With the recent approval of Lyfgenia for sickle cell disease (cost: $3.1 million), Bluebird sells three gene therapies. The other products are Zynteglo for beta thalassemia ($2.8 million) and Skysona for cerebral adrenoleukodystrophy ($3 million). It’s a pure-play commercial gene therapy business. It’s not even trying to develop additional gene therapies currently. R&D expenses are tied to gathering long-term data on its existing products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Readout LOUD podcast: A CRISPR milestone, biotech mixology

WSS

Roche subsidiary Foundation Medicine opens new headquarters

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Anthos stroke drug appears safer than common blood thinner

Hospitals look to new technology to keep health care workers safe

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

World's first CRISPR

knowledge

explore

Bluebird and the case for gene therapy profits

explore

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Wegovy, Zepbound and weight loss drugs that preserve muscle

New air purifier tech could be key to improving indoor air quality

Patient advocates debate FDA's accelerated approval process

After affirmative action ruling, medical educators look to 'holistic review'

World's first CRISPR

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Readout: Lenmeldy, GLP

Hepatitis C has a cure — but many Americans still lack access to it

Food as medicine: Medically tailored meals may get standardized

knowledge

Scientists boost immune system in aging mice by making it youthful

FDA's naming rule on biosimilars has undermined competition

Does good food count as health care? Study aims to find out

Congress must reauthorize a committee to support older Americans

Readout Newsletter: Merck, Vertex, and Viking updates

Decaf coffee targeted by food safety group under obscure FDA rule

knowledge

explore

knowledge

explore